Ovarian Cancer Market

Global Ovarian Cancer Market Size (2024 to 2029)

The size of the global ovarian cancer market is predicted to register a CAGR of 10.1% from 2024 to 2029.

Current Scenario of the Global Ovarian Cancer Market

The formation of mutational cells or tissues in female reproductive organs called ovaries leads to ovarian cancer. Cancer remains undetected until the mutation spreads to the stomach and pelvis, a very advanced stage of ovarian cancer, which is fatal. A substantial percentage of women are dying due to ovarian cancer across the world. Ovarian cancer shows pious symptoms in the affected women, but they might experience pain in the abdomen, fatigue, indigestion, bloating, and nausea.

MARKET DRIVERS

The growing women aging population and rising prevalence of ovarian cancer worldwide are majorly accelerating the growth rate of the global ovarian cancer market.

The increasing economies of the countries in the developed and developing regions are leading to the expansion of healthcare. As a result, they are contributing to the growth of the global ovarian cancer market. The global ovarian cancer market is further predicted to develop in response to the growing geriatric population of women, the rise in ovarian cancer incidence, the ease of use of new treatments and therapies, and the increase in healthcare expenditure. In addition, increased government financing is also fuelling the market's expansion.

Ovarian cancer has become more common in recent years as the female population has aged. Some of the other important reasons driving the growth of the ovarian cancer market are rising ovarian cancer prevalence, the launch of new medications and therapies, increased healthcare expenditure, and increased government funding. Furthermore, growing healthcare awareness is propelling the ovarian cancer market forward. As a result, drugs like Bevacizumab (Avastin) and Pazopanib (Votrient) are expected to enhance the market, now dominated by generics like paclitaxel and carboplatin. In addition, the market is expected to benefit significantly from the development of new medications to treat this form of cancer.

The global ovarian cancer treatment market is boosted by ongoing research and development to offer effective treatment interventions for various disorders. Several ovarian cancer treatments are now in clinical trials and are likely to hit the market in the near future. In addition, the patent expiration of certain top pharmaceuticals may also help propel the industry by encouraging new companies to enter the market. These altering dynamics are predicted to drive the ovarian cancer market during the forecast period. Additionally, the increasing adoption rate of combination therapies for treatment is another significant factor that catalyzes the growth of this market. Increased funding from governments and private organizations to research and develop effective treatment techniques and advanced therapeutics for treating ovarian cancer is boosting the worldwide ovarian cancer market.

MARKET RESTRAINTS

Ovarian cancer symptoms are commonly ignored and readily confused with other illnesses, resulting in a lack of early identification and correct diagnosis.

This is impeding the market for ovarian cancer diagnostics and treatments in Asia-Pacific. Ovarian cancer can spread to other organs such as the abdominal cavity, pelvis, and abdominal lymph nodes, bones, liver, brain, and the sac around the lymph nodes, among other things. Furthermore, the global market's expansion is being stifled by the expiration of significant medication patents. In the development of increasingly effective drugs, the market may confront a problem.In addition, the unavailability of adequate technology for detecting ovarian cancer in the early stages is the major challenge limiting the growth of the global ovarian cancer market. Furthermore, the lack of skilled professionals is challenging the key players in the growth of the market. Also, the lack of funding for research and development activities is challenging the growth of the ovarian cancer market.

REPORT COVERAGE

SEGMENTAL ANALYSIS

Global Ovarian Cancer Market Analysis By Cancer Type

The epithelial ovarian cancer segment is predicted to hold a leading share in the global market during the forecast period based on the cancer type. The rising population and growing awareness of the availability of treatment procedures bolstered the demand for this market. In addition, increasing incidences of ovarian cancer patients propel the growth rate of the ovarian low malignant potential tumor segment.

Global Ovarian Cancer Market Analysis By Type of Treatment

Based on the type of treatment, Immunotherapy is dominating the market. It is presumed to grow at a high pace during the forecast period due to the continually increasing adoption rate of immunotherapy treatments and the expansion of healthcare, leading to the rise in the number of patients diagnosed with ovarian cancer undergoing immunotherapy.The targeted therapy market is continuously increasing at a high rate of CAGR. It is likely to continue the trend during the forecast period due to the increasing popularity of targeted therapies and the rising prevalence of women affected by ovarian cancer.  

REGIONAL ANALYSIS

Geographically, North America accounted for the leading share of the global ovarian cancer market in 2022. It is assumed to continue the trend during the outlook period due to the increasing pervasiveness of ovarian cancer and the geriatric population's growing account. The United States controls the highest share in the ovarian cancer diagnostics and therapeutics market and has added significantly. Ovarian cancer is the ninth most common cancer and the fifth leading cause of cancer death among women in the United States. Furthermore, most of the top global ovarian cancer diagnostics players are based in the United States. Therefore, it tends to be a significant advantage for the region, expected to drive the market.

Asia-Pacific demand is contributing a significant share of revenues to the market. It is likely to witness growth at a high CAGR during the projection period due to the increasing prevalence of the aged population and the growing economies of countries like China and India. India and China are the fastest emerging countries in the Asia Pacific, owing to rising healthcare expenditures, increased government support, and an expanding target patient pool. Every year, more than 7 million new cancer cases are identified in Asia, according to the World Health Organization (WHO). China and India are regarded as two of the most promising countries globally, with substantial market prospects. Rising ovarian cancer incidence, favorable medical care reforms, increased health awareness, a low-cost base, and a lack of legal and cultural barriers contribute to the market's growth in India and China. As a result, the Asia-Pacific ovarian cancer diagnostics market is growing at a rapid pace.

Furthermore, the Asia-Pacific ovarian cancer diagnostics and therapeutics market is being fuelled by increased usage of combination treatments to treat ovarian cancer and rising healthcare spending in particular parts of the region. Ovarian cancer is becoming more common in China, which is leading the market. As a result, the projected incidence of ovarian cancer among Chinese women is rising.

KEY PLAYERS IN THE GLOBAL OVARIAN CANCER MARKET

Companies leading the global ovarian cancer market profiled in the report are Aetera Zenteris Inc., Eli Lilly and Company, Roche, Amgen, Janssen Pharmaceuticals, Inc., Bristol Myers Squibb Company, Novogen Inc., GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, and Genentech Inc.

RECENT HAPPENINGS IN THE MARKET

• GlaxoSmithKline plc has developed a novel drug for women diagnosed with advanced ovarian cancer. The company approved a drug called zejula to the FDA in February 2020; the FDA aims for an efficient reviewing process to make it available for patients.
• In the recent studies, the researchers have identified a new drug fragment; as per the reports published by the research team, the pieces can help analyze the function of cancer protein leading to the development of drugs in the future.

DETAILED SEGMENTATION OF GLOBAL OVARIAN CANCER MARKET INCLUDED IN THIS REPORT

This research report on the global ovarian cancer market has been segmented and sub-segmented based on the stage of cancer, diagnosis, type of treatment, type of cancer, and region.

By Stage of Cancer

• Stage I
  • Stage IA
  • Stage IB
  • Stage IC
• Stage II
  • Stage IIA
  • Stage IIB
  • Stage IIC
• Stage III
  • Stage IIIA
  • Stage IIIB
  • Stage IIIC
• Stage IV

By Cancer Type

• Primary Peritoneal Carcinoma
• Ovarian Stromal Tumors
• Ovarian Germ Cell Tumors
• Epithelial Ovarian Tumors

By Diagnosis

• Physical Examination
• Blood Tests
• Ultrasound
• PET
• CT Scan
• MRI
• Human Chorionic Gonadotropin Test
• Biopsy

By Type of Treatment

• Chemotherapy
• Radiation Therapy
• Hormonal Therapy
• Surgery
• Immunotherapy
• Targeted Therapy

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• The Middle East and Africa